Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $19 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $19 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $143 | $148 | $92 | $58 |
| G&A Expenses | $53 | $42 | $40 | $29 |
| SG&A Expenses | $54 | $42 | $40 | $29 |
| Sales & Mktg Exp. | $1 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$277 | $0 |
| Operating Expenses | $197 | $191 | -$145 | $87 |
| Operating Income | -$197 | -$191 | $145 | -$68 |
| % Margin | – | – | – | -358.7% |
| Other Income/Exp. Net | $29 | $22 | $7 | $0 |
| Pre-Tax Income | -$167 | -$169 | $151 | -$67 |
| Tax Expense | $0 | -$14 | $42 | $0 |
| Net Income | -$167 | -$153 | $111 | -$66 |
| % Margin | – | – | – | -346.1% |
| EPS | -3.11 | -3.69 | 2.46 | -1.48 |
| % Growth | 15.7% | -250% | 266.2% | – |
| EPS Diluted | -3.11 | -3.69 | 2.38 | -1.48 |
| Weighted Avg Shares Out | 54 | 42 | 45 | 44 |
| Weighted Avg Shares Out Dil | 54 | 42 | 47 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $30 | $22 | $7 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$167 | -$190 | -$132 | -$68 |
| % Margin | – | – | – | -358.4% |